| 2019 | 2021 | 2022 (projected) | Consolidated Income | 16.3 B | 18.75 B | 17.02 B | Direct Expenses | 10.22 B | 30.82 B | 33.25 B |
What to know before purchasing Pfizer (NYSE:PFE) based on its volatility?
 | By Ellen Johnson | Macroaxis Story |
13% of stocks are less volatile than Pfizer, and above 99% of all equities are expected to generate higher returns over the next 90 days. While many risk-averse shareholders are getting carried away by overanalyzing healthcare space, it is reasonable to digest Pfizer Inc. What exactly are Pfizer shareholders getting in December?
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Michael Smolkin
Pfizer Inc has roughly 36.13 B in cash with 26.6 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.44. Volatility is a rate at which the price of Pfizer or any other equity instrument increases or decreases for a given set of returns. It is measured by calculating the standard deviation of the annualized returns over a given period of time and shows the range to which the price of Pfizer may increase or decrease. In other words, similar to Pfizer's beta indicator, it measures the risk of Pfizer and helps estimate the fluctuations that may happen in a short period of time. So if prices of Pfizer fluctuate rapidly in a short time span, it is termed to have high volatility, and if it swings slowly in a more extended period, it is understood to have low volatility. Please read more on our technical analysis page.
How important is Pfizer's Liquidity
Pfizer financial leverage refers to using borrowed capital as a funding source to finance Pfizer Inc ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Pfizer financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Pfizer's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Pfizer's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Pfizer's total debt and its cash.
Pfizer Gross Profit
Pfizer Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Pfizer previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Pfizer Gross Profit growth over the last 10 years. Please check Pfizer's gross profit and other fundamental indicators for more details.
Pfizer Volatility Drivers
Pfizer unsystematic risk is unique to Pfizer Inc and usually not directly affected by the market or economic environment. An example of unsystematic risk is the possibility of poor earnings or a layoff due to coronavirus. One may mitigate nonsystematic risk by buying different securities in the same industry or by buying in different sectors. For example, if you have a position in Pfizer you can also buy AbbVie Inc. You can also mitigate this risk by investing in the health care sector as well as in companies having nothing to do with it. This type of risk is also called diversifiable risk and can be understood from analyzing Pfizer important indicators over time. Here we run a correlation analysis between relevant fundamental ratios over at least ten year period to find a relationship in the way they react to changes in Pfizer income statement and balance sheet. Here are more details about Pfizer volatility.Click cells to compare fundamentals
What is driving Pfizer Investor Appetite?
The company reported the last year's revenue of 99.88 B. Total Income to common stockholders was 29.95 B with profit before taxes, overhead, and interest of 50.63 B.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Pfizer Inc. Please refer to our Terms of Use for any information regarding our disclosure principles.